Abstract
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have